IL91822A - A method for cleansing vitamin K-dependent proteins - Google Patents
A method for cleansing vitamin K-dependent proteinsInfo
- Publication number
- IL91822A IL91822A IL9182289A IL9182289A IL91822A IL 91822 A IL91822 A IL 91822A IL 9182289 A IL9182289 A IL 9182289A IL 9182289 A IL9182289 A IL 9182289A IL 91822 A IL91822 A IL 91822A
- Authority
- IL
- Israel
- Prior art keywords
- protein
- ion
- resin
- cation
- under conditions
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 title claims abstract description 35
- 238000000746 purification Methods 0.000 title description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 200
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 200
- 150000001768 cations Chemical class 0.000 claims abstract description 58
- 239000006143 cell culture medium Substances 0.000 claims abstract description 20
- 239000000356 contaminant Substances 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 164
- 239000011347 resin Substances 0.000 claims description 83
- 229920005989 resin Polymers 0.000 claims description 83
- 239000011780 sodium chloride Substances 0.000 claims description 82
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 claims description 77
- 229940100689 human protein c Drugs 0.000 claims description 77
- 239000000463 material Substances 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 39
- 230000002209 hydrophobic effect Effects 0.000 claims description 35
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 31
- 238000005342 ion exchange Methods 0.000 claims description 31
- 239000003456 ion exchange resin Substances 0.000 claims description 31
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 31
- 239000011575 calcium Substances 0.000 claims description 25
- 239000002609 medium Substances 0.000 claims description 22
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 21
- 239000002738 chelating agent Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 claims description 15
- 229910001424 calcium ion Inorganic materials 0.000 claims description 15
- 102000052932 human PROS1 Human genes 0.000 claims description 15
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 14
- -1 anionic amine Chemical class 0.000 claims description 14
- 239000002158 endotoxin Substances 0.000 claims description 14
- 229940099815 human protein s Drugs 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 10
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 10
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 108010045403 Calcium-Binding Proteins Proteins 0.000 claims description 7
- 102000005701 Calcium-Binding Proteins Human genes 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- 229910052788 barium Inorganic materials 0.000 claims description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052712 strontium Inorganic materials 0.000 claims description 4
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 102000029950 cation binding proteins Human genes 0.000 claims description 2
- 108091014789 cation binding proteins Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 241000277331 Salmonidae Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 17
- 238000011084 recovery Methods 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 8
- 238000004587 chromatography analysis Methods 0.000 abstract description 7
- 244000005700 microbiome Species 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 118
- 239000007983 Tris buffer Substances 0.000 description 55
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 55
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 53
- 239000001110 calcium chloride Substances 0.000 description 53
- 229910001628 calcium chloride Inorganic materials 0.000 description 53
- 235000011148 calcium chloride Nutrition 0.000 description 53
- 239000000872 buffer Substances 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 238000010828 elution Methods 0.000 description 24
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000012149 elution buffer Substances 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 8
- 238000005349 anion exchange Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
- 239000006167 equilibration buffer Substances 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- YYLQUHNPNCGKJQ-PIKHSQJKSA-N 3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)C(O)C(O)=O YYLQUHNPNCGKJQ-PIKHSQJKSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101800000135 N-terminal protein Proteins 0.000 description 3
- 101800001452 P1 proteinase Proteins 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 229940012413 factor vii Drugs 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101001049020 Homo sapiens Coagulation factor VII Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229940006612 barium citrate Drugs 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 108010013113 glutamyl carboxylase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 229940099816 human factor vii Drugs 0.000 description 1
- 229940039715 human prothrombin Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000012540 ion exchange chromatography resin Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 102000043253 matrix Gla protein Human genes 0.000 description 1
- 108010057546 matrix Gla protein Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
- C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Enzymes And Modification Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25327988A | 1988-10-04 | 1988-10-04 | |
| US07/393,281 US4981952A (en) | 1988-10-04 | 1989-08-16 | Method for the purification of vitamin K-dependent proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL91822A0 IL91822A0 (en) | 1990-06-10 |
| IL91822A true IL91822A (en) | 2001-06-14 |
Family
ID=26943089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9182289A IL91822A (en) | 1988-10-04 | 1989-09-28 | A method for cleansing vitamin K-dependent proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4981952A (da) |
| EP (1) | EP0363126B2 (da) |
| JP (1) | JP2848461B2 (da) |
| KR (1) | KR0139209B1 (da) |
| AT (1) | ATE106406T1 (da) |
| AU (1) | AU635222B2 (da) |
| CA (1) | CA1314011C (da) |
| DE (1) | DE68915675T3 (da) |
| DK (1) | DK176090B1 (da) |
| ES (1) | ES2054019T5 (da) |
| HU (1) | HU204538B (da) |
| IE (1) | IE63765B1 (da) |
| IL (1) | IL91822A (da) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8729822D0 (en) * | 1987-12-22 | 1988-02-03 | Central Blood Lab Authority | Chemical process |
| DE3833936C1 (da) * | 1988-10-05 | 1989-09-21 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De | |
| DE3911629A1 (de) * | 1989-04-10 | 1990-10-11 | Behringwerke Ag | Verfahren zur abtrennung von toxinen aus proteinloesungen |
| IL97312A (en) | 1990-02-23 | 1999-01-26 | Lilly Co Eli | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
| CA2105282C (en) | 1991-03-01 | 2002-09-24 | Centeon L.L.C. | Preparation of factor ix |
| IT1262899B (it) * | 1992-03-27 | 1996-07-22 | Sclavo Spa | Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano |
| MY110664A (en) * | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| DK38293D0 (da) * | 1993-03-31 | 1993-03-31 | Novo Nordisk As | Fremstilling af proteiner |
| US5618714A (en) * | 1993-12-15 | 1997-04-08 | Eli Lilly And Company | Methods for producing protein C |
| DE4406515C1 (de) * | 1994-02-28 | 1995-10-19 | Immuno Ag | Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine |
| DE4435520A1 (de) * | 1994-10-04 | 1996-04-11 | Immuno Ag | Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US5869604A (en) * | 1995-11-09 | 1999-02-09 | Georgia Institute Of Technology | Crystallization and purification of polypeptides |
| US5910584A (en) * | 1996-09-05 | 1999-06-08 | Asahi Kogaku Kogyo Kabushiki Kaisha | Method for isolating plasmid DNA |
| US5843731A (en) * | 1996-09-05 | 1998-12-01 | Asahi Kogaku Kogyo Kabushiki Kaisha | Method for purifying plasmid DNA on calcium phosphate compound |
| US6630137B1 (en) * | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| EP1557463A1 (en) * | 1997-04-28 | 2005-07-27 | Eli Lilly & Company | Improved methods for processing activated protein C |
| ZA983496B (en) * | 1997-04-28 | 1999-10-25 | Lilly Co Eli | Methods for processing activated protein C. |
| BR9809932A (pt) * | 1997-06-05 | 2000-08-01 | Lilly Co Eli | Métodos para tratamento de distúrbios trombóticos |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| CN1324244A (zh) | 1998-10-22 | 2001-11-28 | 伊莱利利公司 | 治疗脓毒症的方法 |
| DE69930419T2 (de) | 1998-11-13 | 2006-09-07 | Eli Lilly And Co., Indianapolis | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
| ATE235915T1 (de) | 1998-11-20 | 2003-04-15 | Lilly Co Eli | Behandlung von hämorrhagischem virusfieber mit protein c |
| BR9915572A (pt) | 1998-11-23 | 2001-08-14 | Lilly Co Eli | Processo de tratamento de doença de célula falciforme e talassemia |
| US7204981B2 (en) * | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
| EP1289543A2 (en) | 2000-05-24 | 2003-03-12 | Eli Lilly And Company | Formulations and methods for treating hypercoagulable states |
| DE60138111D1 (de) * | 2000-07-21 | 2009-05-07 | Chemo Sero Therapeut Res Inst | Verfahren zur reinigung eines kalziumionen-bindenden proteins |
| WO2002085117A1 (en) * | 2001-04-24 | 2002-10-31 | Eisai Co., Ltd. | Methods and compositions for preventing and treating septic shock and endotoxemia |
| JP2004535461A (ja) * | 2001-07-19 | 2004-11-25 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | プロテインｃの不活性化を抑制するための銅キレート剤の使用 |
| JP4628618B2 (ja) * | 2001-09-26 | 2011-02-09 | 富士フイルム株式会社 | 撮像光学系 |
| US20050143283A1 (en) * | 2002-03-08 | 2005-06-30 | Eli Lilly And Company | Activated protein c formulations |
| WO2004056309A2 (en) | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
| US9192657B2 (en) * | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| EP1651252B1 (en) * | 2003-07-08 | 2014-11-26 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| JP2008507561A (ja) * | 2004-07-23 | 2008-03-13 | ザ ユニバーシティ オブ ロチェスター | 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害 |
| JP2008525381A (ja) | 2004-12-23 | 2008-07-17 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少 |
| US20090047723A1 (en) * | 2005-01-14 | 2009-02-19 | Bayer Healthcare Llc | Method for purification of factor vii |
| BRPI0613137A2 (pt) * | 2005-06-24 | 2010-12-21 | Drugrecure Aps | administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório |
| WO2007071767A1 (en) * | 2005-12-23 | 2007-06-28 | Novo Nordisk Health Care Ag | Purification of vitamin k-dependent polypeptides using preparative reverse phase chromatography (rpc) |
| HRP20160990T1 (hr) | 2006-03-24 | 2016-10-07 | Biogen Hemophilia Inc. | Pc5 kao enzim obrade faktor ix propeptida |
| US20100284997A1 (en) * | 2006-10-31 | 2010-11-11 | Griffin John H | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
| DK2125866T3 (da) | 2007-02-28 | 2013-07-29 | Baxter Int | Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler |
| CA2683423C (en) | 2007-04-26 | 2020-10-27 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |
| HUE037162T2 (hu) | 2007-07-09 | 2018-08-28 | Genentech Inc | Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során |
| CA2742246A1 (en) | 2008-12-02 | 2010-06-10 | Novo Nordisk Health Care Ag | Polypeptide purification |
| EP2199387A1 (en) | 2008-12-19 | 2010-06-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serine protease derivatives and uses for the prevention and/or the treatment of blood coagulation disorders |
| ES2629099T3 (es) | 2008-12-19 | 2017-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea |
| EP2494040B1 (en) | 2009-10-30 | 2018-08-29 | Aptevo BioTherapeutics LLC | Method of producing recombinant vitamin k dependent proteins |
| EP2526115B1 (en) | 2010-01-18 | 2018-08-01 | Novo Nordisk Health Care AG | Purification of blood coagulation factors |
| JP5883849B2 (ja) * | 2010-04-29 | 2016-03-15 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 陰イオン交換樹脂を用いる二価カチオン結合タンパク質の精製方法 |
| JP6147726B2 (ja) | 2011-03-29 | 2017-06-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | タンパク質精製のためのバッファー系 |
| CA2847818A1 (en) * | 2011-09-06 | 2013-03-14 | Medimmune, Llc | Methods for processing coagulation factors |
| EP2748180B1 (en) * | 2011-10-14 | 2018-08-15 | Baxalta GmbH | Protein purification by anion exchange chromatography |
| LT2748179T (lt) * | 2011-10-14 | 2022-04-11 | Takeda Pharmaceutical Company Limited | Baltymų gryninimas anijonų mainų chromatografija |
| ES2676422T3 (es) | 2012-07-04 | 2018-07-19 | Zz Biotech Llc | Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel |
| TR201808584T4 (tr) * | 2013-03-15 | 2018-07-23 | Baxalta GmbH | Anyon değişimi kromotografisi aracılığıyla k vitaminine bağlı proteinler için saflaştırma yöntemi. |
| ES2890675T3 (es) | 2014-04-16 | 2022-01-21 | Zz Biotech Llc | APC para uso en el tratamiento de cicatrices cutáneas anormales |
| PT3131572T (pt) | 2014-04-16 | 2021-09-24 | Zz Biotech Llc | Análogo de apc para utilização em cicatrização de feridas |
| AU2017205364B2 (en) * | 2016-01-07 | 2021-03-04 | Eio Biomedical Ltd | Methods, compositions and kits for reducing tissue adhesions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4512992A (en) * | 1980-06-13 | 1985-04-23 | Burroughs Wellcome Co. | Treatment with dialkoxy pyridopyrimidine compounds |
| DE3101752A1 (de) * | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen" |
| US4599197A (en) * | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4518526A (en) * | 1982-12-22 | 1985-05-21 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4766224A (en) * | 1985-08-19 | 1988-08-23 | International Minerals & Chemical Corp. | Purification and activation of proteins from insoluble inclusion bodies |
| US4677196A (en) * | 1985-09-06 | 1987-06-30 | International Minerals & Chemical Corp. | Purification and activation of proteins from insoluble inclusion bodies |
| US4786726A (en) * | 1986-01-06 | 1988-11-22 | Blood Systems, Inc. | Factor IX therapeutic blood product, means and methods of preparing same |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| DE3615558A1 (de) * | 1986-05-09 | 1987-11-12 | Behringwerke Ag | Verfahren zur herstellung eines faktor v-konzentrats |
-
1989
- 1989-08-16 US US07/393,281 patent/US4981952A/en not_active Expired - Lifetime
- 1989-09-27 CA CA000613553A patent/CA1314011C/en not_active Expired - Lifetime
- 1989-09-28 IL IL9182289A patent/IL91822A/en not_active IP Right Cessation
- 1989-10-02 EP EP89310061A patent/EP0363126B2/en not_active Expired - Lifetime
- 1989-10-02 ES ES89310061T patent/ES2054019T5/es not_active Expired - Lifetime
- 1989-10-02 DE DE68915675T patent/DE68915675T3/de not_active Expired - Lifetime
- 1989-10-02 AT AT89310061T patent/ATE106406T1/de not_active IP Right Cessation
- 1989-10-03 DK DK198904855A patent/DK176090B1/da not_active IP Right Cessation
- 1989-10-03 IE IE315989A patent/IE63765B1/en not_active IP Right Cessation
- 1989-10-03 AU AU42519/89A patent/AU635222B2/en not_active Ceased
- 1989-10-03 JP JP1259873A patent/JP2848461B2/ja not_active Expired - Lifetime
- 1989-10-03 HU HU895158A patent/HU204538B/hu not_active IP Right Cessation
- 1989-10-04 KR KR1019890014186A patent/KR0139209B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE106406T1 (de) | 1994-06-15 |
| US4981952A (en) | 1991-01-01 |
| ES2054019T3 (es) | 1994-08-01 |
| HUT53373A (en) | 1990-10-28 |
| EP0363126B1 (en) | 1994-06-01 |
| ES2054019T5 (es) | 2002-10-16 |
| DK485589A (da) | 1990-04-05 |
| JPH02200180A (ja) | 1990-08-08 |
| HU204538B (en) | 1992-01-28 |
| AU635222B2 (en) | 1993-03-18 |
| AU4251989A (en) | 1990-04-12 |
| EP0363126B2 (en) | 2002-03-06 |
| IE893159L (en) | 1990-04-04 |
| DE68915675T3 (de) | 2002-08-14 |
| DK176090B1 (da) | 2006-05-22 |
| CA1314011C (en) | 1993-03-02 |
| DK485589D0 (da) | 1989-10-03 |
| EP0363126A2 (en) | 1990-04-11 |
| JP2848461B2 (ja) | 1999-01-20 |
| KR0139209B1 (ko) | 1998-04-30 |
| KR900006511A (ko) | 1990-05-08 |
| DE68915675D1 (de) | 1994-07-07 |
| IE63765B1 (en) | 1995-06-14 |
| IL91822A0 (en) | 1990-06-10 |
| EP0363126A3 (en) | 1991-09-11 |
| DE68915675T2 (de) | 1994-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0363126B1 (en) | Method for the purification of vitamin K-dependent proteins | |
| RU2458067C2 (ru) | Способ выделения плазминогена или плазмина в присутствии фибриногена из смеси | |
| EP4299735B1 (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| CA2220501A1 (en) | Novel factor ix purification methods | |
| CN103025757A (zh) | 二价阳离子结合蛋白在阴离子交换树脂上的纯化方法 | |
| CA2143510C (en) | Method for the isolation and purification of vitamin k-dependent proteins | |
| CA2105282C (en) | Preparation of factor ix | |
| US5831025A (en) | Human activated protein C and process for preparing same | |
| Pixley et al. | [4] Factor XII: Hageman factor | |
| US6010844A (en) | Methods of preparing and recovering proteins | |
| EP1015568B1 (en) | METHOD FOR THE PRODUCTION OF rDSPA Alpha1 | |
| US20090093038A1 (en) | Method for the production of pure virally inactivated butyrylcholinesterase | |
| AU4311893A (en) | Purification of kringle containing proteins, and especially t-pa | |
| JPH03219892A (ja) | タンパク質の製造法 | |
| HK40103492B (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK40103492A (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK1241929B (en) | Methods of purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK1171784A (en) | Method for purifying recombinant adamts13 and other proteins and compositions thereof | |
| HK1171784B (en) | Method for purifying recombinant adamts13 and other proteins and compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| RH1 | Patent not in force |